Chongqing Pharscin Pharmaceutical Co., Ltd. (SHE:002907)
14.86
+0.05 (0.34%)
Feb 3, 2026, 3:04 PM CST
SHE:002907 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 775.83 | 764.14 | 680.84 | 774.72 | 837.23 | 876.09 |
Other Revenue | 10.68 | 10.68 | 10.7 | 10.47 | 8.91 | 6.38 |
| 786.51 | 774.82 | 691.54 | 785.18 | 846.14 | 882.47 | |
Revenue Growth (YoY) | -0.51% | 12.04% | -11.93% | -7.20% | -4.12% | 4.80% |
Cost of Revenue | 334.55 | 332.91 | 312.45 | 320.55 | 400.53 | 458.88 |
Gross Profit | 451.96 | 441.91 | 379.1 | 464.63 | 445.61 | 423.59 |
Selling, General & Admin | 305.69 | 308.36 | 263.88 | 292.53 | 297.82 | 269.07 |
Research & Development | 79.38 | 59.13 | 78.12 | 58.82 | 41.72 | 36.48 |
Other Operating Expenses | 27.77 | 10.65 | 9.39 | 12.34 | 11.58 | 9.82 |
Operating Expenses | 411.53 | 379.55 | 349.7 | 367.04 | 350.65 | 314.47 |
Operating Income | 40.42 | 62.36 | 29.4 | 97.59 | 94.95 | 109.13 |
Interest Expense | - | - | -0.95 | -14.42 | -18.22 | -17.21 |
Interest & Investment Income | 24.02 | 10.32 | 9.81 | 11.5 | 16.4 | 14.61 |
Currency Exchange Gain (Loss) | 0 | 0 | -0 | - | - | - |
Other Non Operating Income (Expenses) | -16.05 | 0.27 | -0.17 | -0.03 | -0.03 | -0.02 |
EBT Excluding Unusual Items | 48.39 | 72.95 | 38.1 | 94.64 | 93.11 | 106.51 |
Gain (Loss) on Sale of Investments | 5.54 | 1.38 | -4.67 | -2.61 | -1.33 | 1.21 |
Gain (Loss) on Sale of Assets | 8.56 | - | 0.06 | - | -0.01 | -0.01 |
Asset Writedown | 0.63 | -0.03 | -2.37 | -0.17 | - | - |
Other Unusual Items | 31.19 | 19.14 | 11.68 | 16.37 | 11.65 | 29.34 |
Pretax Income | 94.32 | 93.44 | 42.8 | 108.24 | 103.42 | 137.05 |
Income Tax Expense | 24.24 | 16.71 | 10.1 | 9.84 | 11.64 | 17.86 |
Earnings From Continuing Operations | 70.07 | 76.73 | 32.7 | 98.4 | 91.78 | 119.19 |
Minority Interest in Earnings | 4.54 | - | - | - | - | - |
Net Income | 74.61 | 76.73 | 32.7 | 98.4 | 91.78 | 119.19 |
Net Income to Common | 74.61 | 76.73 | 32.7 | 98.4 | 91.78 | 119.19 |
Net Income Growth | 19.37% | 134.66% | -66.77% | 7.21% | -22.99% | -29.79% |
Shares Outstanding (Basic) | 418 | 418 | 418 | 403 | 401 | 401 |
Shares Outstanding (Diluted) | 418 | 418 | 418 | 403 | 401 | 401 |
Shares Change (YoY) | 0.05% | 0.02% | 3.60% | 0.49% | 0.06% | 0.21% |
EPS (Basic) | 0.18 | 0.18 | 0.08 | 0.24 | 0.23 | 0.30 |
EPS (Diluted) | 0.18 | 0.18 | 0.08 | 0.24 | 0.23 | 0.30 |
EPS Growth | 19.32% | 134.61% | -67.92% | 6.69% | -23.04% | -29.93% |
Free Cash Flow | 67.05 | 145.62 | 126.52 | -47.57 | 26.21 | 66.95 |
Free Cash Flow Per Share | 0.16 | 0.35 | 0.30 | -0.12 | 0.07 | 0.17 |
Dividend Per Share | 0.085 | 0.085 | 0.050 | 0.070 | 0.050 | 0.028 |
Dividend Growth | - | 70.00% | -28.57% | 40.00% | 78.57% | -36.36% |
Gross Margin | 57.46% | 57.03% | 54.82% | 59.17% | 52.66% | 48.00% |
Operating Margin | 5.14% | 8.05% | 4.25% | 12.43% | 11.22% | 12.37% |
Profit Margin | 9.49% | 9.90% | 4.73% | 12.53% | 10.85% | 13.51% |
Free Cash Flow Margin | 8.53% | 18.79% | 18.30% | -6.06% | 3.10% | 7.59% |
EBITDA | 127.78 | 147.38 | 111.3 | 172.13 | 164.7 | 156.02 |
EBITDA Margin | 16.25% | 19.02% | 16.09% | 21.92% | 19.46% | 17.68% |
D&A For EBITDA | 87.35 | 85.01 | 81.9 | 74.54 | 69.74 | 46.89 |
EBIT | 40.42 | 62.36 | 29.4 | 97.59 | 94.95 | 109.13 |
EBIT Margin | 5.14% | 8.05% | 4.25% | 12.43% | 11.22% | 12.37% |
Effective Tax Rate | 25.70% | 17.89% | 23.59% | 9.09% | 11.25% | 13.03% |
Revenue as Reported | 786.51 | 774.82 | 691.54 | 785.18 | 846.14 | 882.47 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.